Loading…
Unjha Formulations (BSE 531762)₹28.25+2.54%Pharmaceuticals
Unjha Formulations is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 26.7 against a peer median of 22.3, and ROCE of 27.7% against a peer median of 6.6%, and latest-quarter sales growth of −8.8% against a peer median of −8.8%. By market cap it is #8 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mono Pharmacare | 18 | 52.6 | 5.0 | 1.1 | 1.78 | 0.0 | 166 | 0 | 22.1 | −100.0 | vs BSE 531762 |
| Centuple Global | 18 | 11.6 | 15.0 | 12.7 | 0.29 | 0.0 | 575 | 2 | 1,07,642.3 | −1,040.0 | vs BSE 531762 |
| Colinz Laboratories | 18 | 6.4 | 7.2 | 5.3 | 0.04 | 0.0 | 6 | 1 | −21.2 | 1,753.8 | vs BSE 531762 |
| Zenith Health Care | 17 | — | 0.3 | 0.1 | 0.00 | 0.0 | 10 | 0 | −23.7 | −430.0 | vs BSE 531762 |
| Starsource Multitrade | 17 | — | −163.9 | −164.0 | 0.00 | 0.0 | 1 | −12 | — | — | vs BSE 531762 |
| Desh Rakshak Aushdhalaya | 14 | 22.3 | 6.6 | 4.9 | 0.21 | 0.0 | 7 | 1 | −21.5 | −17.1 | vs BSE 531762 |
| Beryl Drugs | 13 | 31.1 | 7.2 | 4.3 | 0.25 | 0.0 | 19 | 0 | 4.8 | 292.9 | vs BSE 531762 |
| Unjha Formulations | 13 | 26.7 | 27.7 | 20.1 | 0.00 | 0.0 | 16 | 1 | −8.8 | −57.5 | — |
| ORTIN GLOBAL | 11 | — | −32.1 | −46.0 | 0.81 | 0.0 | 0 | −1 | 262.5 | — | vs BSE 531762 |
| Dipna Pharmachem | 11 | 4.2 | 8.1 | 5.3 | 0.21 | 0.0 | 129 | 3 | −87.2 | −62.7 | vs BSE 531762 |
| Adline Chem Lab | 9 | — | −933.4 | — | — | 0.0 | 0 | −0 | — | −145.5 | vs BSE 531762 |
| Peer median | 14 | 22.3 | 6.6 | 4.6 | 0.21 | 0.0 | 10 | 0 | −8.8 | −62.7 |
Listed companies closest to Unjha Formulations in Pharmaceuticals include Mono Pharmacare, Centuple Global, Colinz Laboratories, Zenith Health Care, Starsource Multitrade, Desh Rakshak Aushdhalaya, Beryl Drugs, ORTIN GLOBAL.
Mono Pharmacare, with a market cap of ₹17.70 Cr.
Unjha Formulations trades at a P/E of 26.7; the median of its peer set is 22.3. A P/E above or below the median is a description, not a judgement on value.
Unjha Formulations' return on capital employed is 27.7%, above the peer median of 6.6%.